Avalon Globocare CorpNASDAQ:ALBT
- LAST PRICE3.3000
- TODAY'S CHANGE (%)-0.0700 (-2.0772%)
- Bid / Lots3.2200/ 1
- Ask / Lots3.2900/ 1
- Open / Previous Close3.3100 / 3.3700
- Day Range
- 52 Week Range
- Volume12,615
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALBT |
|---|---|---|
| 09:32 ET | 1073 | 3.31 |
| 09:39 ET | 100 | 3.43 |
| 09:48 ET | 174 | 3.32 |
| 10:00 ET | 280 | 3.35 |
| 10:18 ET | 350 | 3.3513 |
| 10:20 ET | 200 | 3.3985 |
| 10:31 ET | 1357 | 3.3502 |
| 10:49 ET | 1790 | 3.3201 |
| 10:51 ET | 1159 | 3.32 |
| 11:07 ET | 200 | 3.3118 |
| 11:30 ET | 710 | 3.3796 |
| 11:38 ET | 300 | 3.37 |
| 12:03 ET | 324 | 3.3001 |
| 12:21 ET | 100 | 3.33 |
| 12:24 ET | 2084 | 3.3 |
Jan 23, 2023
Jan 17, 2023
BRIEF-Avalon GloboCare Announces Issuance Of Key U.S. Patent For Multiple Novel QTY-Code Modified Cytokine And Chemokine Protein Receptor Molecules, from 9:24AM ET on Tuesday Jan 17, 2023 by Thomson Reuters
9:24AM ET on Tuesday Jan 17, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Avalon Globocare Corp | 33.7M | -25.6x | --- |
Evogene Ltd | 30.9M | -1.0x | --- |
Marker Therapeutics Inc | 29.5M | -6.9x | --- |
Immix Biopharma Inc | 33.6M | -0.7x | --- |
Better Therapeutics Inc | 34.0M | -0.5x | --- |
TFF Pharmaceuticals Inc | 34.4M | -0.7x | --- |
Company Information
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, CellTech bio-developer. The Company provides immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics, and therapeutics. It operates through two segments: real property and medical related consulting services. Its major clinical programs include AVA-001, AVA-011 and FLASH-CAR, ACTEX, and AVA-Trap. It also provides strategic advisory and outsourcing services to facilitate and enhance its client's growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its services include research studies, executive education, daily online executive briefings, expert advisory services, and consulting and management services.
Contact Information
- Headquarters
- 4400 ROUTE 9, SUITE 3100FREEHOLD, NJ, United States 07728
- Phone
- 732-780-4400
- Fax
- 732-780-5600
Executives
- Chairman of the Board of Directors
- Wenzhao Lu
- President, Chief Executive Officer, Director
- David Jin
- Chief Financial Officer
- Luisa Ingargiola
- Chief Operating Officer, Director
- Sarah Cox
- Director
- Lourdes Felix
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.7M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 10.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-0.13 |
Book Value | $0.03 |
P/E Ratio | -25.6x |
Price/Sales (TTM) | 27.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -711.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
